Ohr releases new interim data on Squalamine eye drops
Ohr Pharmaceuticals reported additional interim data from its phase 2 study on Squalamine eye drops for the treatment of wet age-related macular degeneration.
Data showed eyes that received a combination of Squalamine eye drops (OHR-102) and as-needed dosing of Lucentis (ranibizumab, Genentech) had visual acuity and anatomical benefits compared with patients who received placebo eye drops in combination with as-needed dosing of ranibizumab. Jason S. Slakter, MD, chief medical officer of Ohr, presented the new interim data at the American Society of Retina Specialists annual meeting.
The interim analysis included the first 29 patients of the OHR-102 arm and 33 patients of the placebo arm who completed the 9-month treatment protocol of the original IMPACT study.
During the interim analysis, 48.3% of patients in the OHR-102 group had gains in best corrected visual acuity of 15 letters or more, compared with 21.2% of patients in the placebo group, according to a company press release.
Mean gain in visual acuity was +10.4 letters in the OHR-102 group compared with +6.3 letters in the placebo group. Additionally, mean change central subfield thickness was −139 µm in the OHR-102 group compared with −117 µm in the placebo group.
Among patients with a lesion containing a classic component and a size of up to 12 disc areas, 67% of OHR-102 patients had BCVA gains of three or more lines compared with 20% in the placebo group.
Patients who received OHR-102 were more than three times as likely to gain four to five or more lines of vision compared with patients in the placebo group, according to the release.
Disclosure: Slakter has received grant research support (DARC) from Bayer, Genentech, Ohr and Regeneron; is a consultant for Genentech and Ohr; and has stock ownership in Ohr.